文献速递核素与放射性配体治疗肿瘤 PET/CT

全切或部分肾上腺切除术治疗醛固酮瘤:68Ga-Pentixafor PET/CT能否预测手术结局

Total or partial adrenalectomy for aldosterone-producing adenoma: can 68Ga-Pentixafor PET/CT predict surgical outcomes?
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-04-04

该前瞻性随机研究纳入187例原发性醛固酮增多症患者,比较68Ga-Pentixafor PET/CT与肾上腺静脉采血(AVS)预测肾上腺切除术后功能结局的准确性。90例手术患者随机接受部分或全肾上腺切除术,PET/CT预测各项PASO成功的准确率为67.78%–78.89%,AVS为54.44%–74.44%,差异在预设的非劣效界值-10%以内。SUVmax是临床完全成功的独立预测因素,最佳切点为9.8。

要点

  • PET/CT预测PASO各项成功的准确率为67.78%–78.89%,AVS为54.44%–74.44%,差异在预设-10%非劣效界值内。
  • 部分与全肾上腺切除组功能结局无显著差异。
  • SUVmax是临床完全成功的独立因素,AUC 0.896,最佳切点9.8。

核心结论

  • 68Ga-Pentixafor PET/CT预测肾上腺切除术后功能结局的准确性可与有创的AVS相媲美。
  • SUVmax是临床完全成功的独立因素,可能预测腹腔镜肾上腺切除术的功能结局。
  • 作者建议对SUVmax超过9.8的个体行腹腔镜部分肾上腺切除术。
  • PET/CT定位醛固酮瘤最终为采用更局限的治疗选择铺平道路。

研究设计与样本

  • 前瞻性研究,纳入诊断为原发性醛固酮增多症(PA)的患者。
  • 所有患者接受68Ga-Pentixafor PET/CT和AVS,由多学科团队讨论患者管理。
  • 90例适合手术的患者随机分为部分肾上腺切除术组(n=45)和全肾上腺切除术组(n=45),另97例接受药物治疗。
  • 术后以PASO标准作为金标准。
  • 试验注册号ChiCTR2300070830,注册日期2023年4月23日。

主要发现

  • 共187例PA患者接受68Ga-Pentixafor PET/CT和AVS检查,其中90例手术患者纳入分析。
  • 68Ga-Pentixafor PET/CT正确预测生化部分或完全成功、生化完全成功、临床部分或完全成功、临床完全成功的准确率分别为78.89%、77.78%、77.67%、67.78%。
  • AVS对应的准确率分别为74.44%、73.33%、70.00%、54.44%。
  • 68Ga-Pentixafor PET/CT未显著优于AVS,但差异在预设的-10%非劣效界值以内。
  • 部分与全肾上腺切除术组功能结局无显著差异。

关键数值与推荐

  • 68Ga-Pentixafor PET/CT预测生化部分或完全成功准确率78.89%,AVS 74.44%。
  • 68Ga-Pentixafor PET/CT预测生化完全成功准确率77.78%,AVS 73.33%。
  • 68Ga-Pentixafor PET/CT预测临床部分或完全成功准确率77.67%,AVS 70.00%。
  • 68Ga-Pentixafor PET/CT预测临床完全成功准确率67.78%,AVS 54.44%。
  • SUVmax判定临床完全成功的AUC为0.896,最佳切点9.8。

临床怎么用

  • 作者建议对SUVmax超过9.8的个体行腹腔镜部分肾上腺切除术。
  • 对于SUVmax低于9.8的患者,腹腔镜全肾上腺切除术结果优于部分肾上腺切除术。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to compare the accuracy of adrenal vein sampling (AVS) and 68Ga-Pentixafor positron emission tomography (PET)/computed tomography (CT) in predicting the functional outcome from adrenalectomy in patients with primary aldosteronism (PA), and to investigate the utility of 68Ga-Pentixafor PET/CT in laparoscopic partial adrenalectomy. METHODS: We prospectively enrolled patients diagnosed with PA. All patients underwent 68Ga-Pentixafor PET/CT and AVS. Patient management was discussed by a multidisciplinary team. Ninety surgically eligible patients were randomized to partial (n = 45) or total adrenalectomy (n = 45), while 97 received medical therapy. Postoperative Aldosterone Surgical Outcome (PASO) criteria served as the gold standard. RESULTS: In total, 187 patients with PA were examined using 68Ga-pentixafor PET/CT and AVS, and 90 patients who underwent surgery were included in the analysis. The accuracy of 68Ga-Pentixafor PET/CT in correctly predicting biomedical partial or complete success, biomedical complete success, clinical partial or complete success, and clinical complete success was 78.89%, 77.78%, 77.67%, and 67.78%, respectively. For AVS, the accuracies were 74.44%, 73.33%, 70.00%, and 54.44%, respectively. 68Ga-pentixafor PET/CT was not significantly superior, but the differences lay within the pre-specified - 10% margin for non-inferiority. Functional outcomes did not significantly differ between the partial and total adrenalectomy groups. Multivariable logistic analysis demonstrated that the lower highest systolic blood pressure and higher SUVmax were independent factors of complete clinical success. The AUC for SUVmax in determining clinical complete success was 0.896, with an optimal cutoff value of 9.8. Subgroup analysis showed no functional outcome difference between laparoscopic partial and total adrenalectomy for patients with an SUVmax over 9.8. However, for those with an SUVmax below 9.8, laparoscopic total adrenalectomy yielded better results than laparoscopic partial adrenalectomy. CONCLUSION: The accuracy of 68Ga-Pentixafor PET/CT is comparable to the conventional, invasive method of AVS in forecasting the functional outcomes of adrenalectomy. SUVmax is an independent factor in determining complete clinical success and can potentially predict the functional outcome of laparoscopic adrenalectomy. It is suggested that laparoscopic partial adrenalectomy be performed on individuals who present an SUVmax value exceeding 9.8. The ability of 68Ga-Pentixafor PET/CT to localize aldosterone-producing adenoma ultimately paves the way for the use of more focal treatment options. TRIAL REGISTRATION: ChiCTR2300070830. Registered 23 April 2023.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Zheng WC, Chen SM, Qiu QR, et al. Total or partial adrenalectomy for aldosterone-producing adenoma: can 68Ga-Pentixafor PET/CT predict surgical outcomes? Eur J Nucl Med Mol Imaging. 2025. PMID: 40183955. doi:10.1007/s00259-025-07244-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。